Table 1.

Effects of mutations on [³H]ryanodine binding to RyR2

Mutation	EC50 (μM) of Ca2+ activation	Adjusted p value	Basal activity (pmol/mg)	Adjusted p value	n
A. Disease-associated mutations
RyR2 WT	0.23 ± 0.02		3.8 × 10−3 ± 2.3 × 10−3		5
P4902S	0.19 ± 0.01	0.0042	5.8 × 10−3 ± 1.7 × 10−3	0.5207	4
P4902L	0.21 ± 0.02	0.0873	1.1 × 10−3 ± 6.2 × 10−4	0.1692	5
E4950K	0.19 ± 0.01	0.0039	1.7 × 10−3 ± 8.9 × 10−4	0.3388	5
G4955E	0.08 ± 0.00	<0.0001	1.0 × 10−1 ± 1.0 × 10−2	0.001	4
EC50 ANOVA summary: F = 50.5, p < 0.0001; basal activity ANOVA summary: F = 346.5, p < 0.0001
B. Other mutations
RyR2 WT	0.23 ± 0.02		3.8 × 10−3 ± 2.3 × 10−3		5
P4902D	0.07 ± 0.01	<0.0001	9.9 × 10−2 ± 2.5 × 10−2	0.0048	5
P4902K	0.15 ± 0.02	0.0003	1.2 × 10−2 ± 1.2 × 10−2	0.6652	4
G4955D	0.08 ± 0.02	<0.0001	1.1 × 10−1 ± 1.8 × 10−2	0.0055	4
G4955K	0.47 ± 0.04	<0.0001	1.2 × 10−4 ± 2.4 × 10−4	0.0984	4
G4955L	0.31 ± 0.02	0.0002	2.0 × 10−4 ± 4.0 × 10−4	0.1082	4
D4956A	0.26 ± 0.03	0.3966	1.3 × 10−3 ± 1.5 × 10−3	0.3369	5
EC50 ANOVA summary: F = 142.7, p < 0.0001; basal activity ANOVA summary: F = 71.9, p < 0.0001

Data are presented as mean ± SD. The significance of differences in EC₅₀ and basal activity between WT and mutants was evaluated by performing one-way ANOVA with Dunnett's multiple comparisons post hoc testing. A p < 0.05 was considered statistically significant.